Literature DB >> 27299806

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.

K Martin1, J Beyer-Westendorf2, B L Davidson3, M V Huisman4, P M Sandset5, S Moll1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27299806      PMCID： PMC4936273          DOI： 10.1111/jth.13323

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


× No keyword cloud information.
  27 in total

1.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.

Authors:  Harry R Büller; Hervé Décousus; Michael A Grosso; Michele Mercuri; Saskia Middeldorp; Martin H Prins; Gary E Raskob; Sebastian M Schellong; Lee Schwocho; Annelise Segers; Minggao Shi; Peter Verhamme; Phil Wells
Journal:  N Engl J Med       Date:  2013-08-31       Impact factor: 91.245

2.  Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.

Authors:  Suzanne J Francart; Emily M Hawes; Allison M Deal; Dorothy M Adcock; Robert Gosselin; Cheryl Jeanneret; Kenneth D Friedman; Stephan Moll
Journal:  Thromb Haemost       Date:  2014-01-09       Impact factor: 5.249

3.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).

Authors:  Paul A Reilly; Thorsten Lehr; Sebastian Haertter; Stuart J Connolly; Salim Yusuf; John W Eikelboom; Michael D Ezekowitz; Gerhard Nehmiz; Susan Wang; Lars Wallentin
Journal:  J Am Coll Cardiol       Date:  2013-09-27       Impact factor: 24.094

4.  Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation.

Authors:  Mika Skeppholm; Fadiea Al-Aieshy; Maria Berndtsson; Faris Al-Khalili; Yuko Rönquist-Nii; Lisbeth Söderblom; Annika Y Östlund; Anton Pohanka; Jovan Antovic; Rickard E Malmström
Journal:  Thromb Res       Date:  2015-04-30       Impact factor: 3.944

5.  Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Authors:  Wolfgang Mueck; Anthonie W A Lensing; Giancarlo Agnelli; Hervé Decousus; Paolo Prandoni; Frank Misselwitz
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

7.  Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.

Authors:  Bengt I Eriksson; Ola E Dahl; Martin Feuring; Andreas Clemens; Herbert Noack; Stefan Hantel; Richard J Friedman; Michael Huo
Journal:  Thromb Res       Date:  2012-07-26       Impact factor: 3.944

8.  Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.

Authors:  Vijay V Upreti; Jessie Wang; Yu Chen Barrett; Wonkyung Byon; Rebecca A Boyd; Janice Pursley; Frank P LaCreta; Charles E Frost
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

9.  Population pharmacokinetic-pharmacodynamic modeling analysis of intrinsic FXa and bleeding from edoxaban treatment.

Authors:  SaeHeum Song; Dongwoo Kang; Abdel-Baset Halim; Raymond Miller
Journal:  J Clin Pharmacol       Date:  2014-05-02       Impact factor: 3.126

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  65 in total

Review 1.  Initiating and Managing Patients with Venous Thromboembolism on Anticoagulant Drugs: A Practical Overview.

Authors:  Raj S Kasthuri; Stephan Moll
Journal:  Semin Intervent Radiol       Date:  2017-03       Impact factor: 1.513

2.  Therapeutic Enoxaparin in the Morbidly Obese Patient: A Case Report and Review of the Literature.

Authors:  Claudia M Hanni; Sheila M Wilhelm; Bianca Korkis; Elizabeth A Petrovitch; Kanella V Tsilimingras; Sean M McConachie
Journal:  Hosp Pharm       Date:  2018-09-22

3.  Should we monitor the direct oral anticoagulants?

Authors:  Robert Diep; David Garcia
Journal:  J Thromb Thrombolysis       Date:  2020-07       Impact factor: 2.300

4.  Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs).

Authors:  Indrajit Chattopadhyay; Vedamurthy Adhiyaman; Suhani Ghiya
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

5.  Key topics in pulmonary vascular diseases (assembly 13) from the European Respiratory Society 2018 Parisian Congress.

Authors:  Sheila Ramjug; Anton Vonk Noordegraaf; Marion Delcroix
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

6.  Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients.

Authors:  Mouhand F H Mohamed; Hazem Elewa; Mahmood Mubasher; Mohammed Danjuma
Journal:  J Thromb Thrombolysis       Date:  2021-04       Impact factor: 2.300

7.  Rivaroxaban for a Patient with Class III Obesity: Case Report with Literature Review.

Authors:  Duane Bates; Jenny Edwards; Jeffrey Shrum; Casey Chan; Sharita Manga; Elizabeth MacKay
Journal:  Can J Hosp Pharm       Date:  2018-03-07

8.  Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL.

Authors:  Armando Tripodi; Walter Ageno; Marcello Ciaccio; Cristina Legnani; Giuseppe Lippi; Cesare Manotti; Rossella Marcucci; Marco Moia; Benedetto Morelli; Daniela Poli; Agostino Steffan; Sophie Testa
Journal:  Blood Transfus       Date:  2017-09-13       Impact factor: 3.443

Review 9.  [Anticoagulation-direct oral anticoagulants].

Authors:  B Kemkes-Matthes
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

10.  Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study.

Authors:  Megan Z Roberts; G Eric Gaskill; Julie Kanter-Washko; T Rogers Kyle; Brittany C Jones; Nicole M Bohm
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.